aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor

aTyr Pharma has entered into a research collaboration with Albert Einstein College of Medicine to develop and test its monoclonal antibody, ATYR2810, which targets the neuropilin-2 receptor. The collaboration will be led by Dr. Bang H. Hoang, focusing on the role of NRP2 in pediatric bone cancers. ATYR2810 has shown anti-tumor effects in various preclinical models, including non-small cell lung cancer and glioblastoma, with findings presented at major scientific conferences.